The recent Drug Information Association (DIA) 50th Annual Meeting served as a global connector for professionals across the life science product development lifecycle. Last month’s conference in San Diego focused on the exchange of information across multiple disciplines and assembled an estimated 7,000 industry professionals. Many of our clients, partners and competitors led sessions and panels on innovative partnering models, processes and technologies in clinical research, and transformation. This year’s conference theme was “Celebrate the Past - Invent the Future” and it was clear that technology is a key driver for attendees as they focus on advancing medical science and bringing new innovations to patient communities around the world.
Advancing life sciences innovation and benefiting from a standardized platform
Accenture’s Accelerated R&D Services presence at DIA encouraged visitors to embrace this journey to “Invent the Future” by rethinking, reshaping, restructuring R&D. During the conference, we had numerous conversations with global life sciences companies interested in learning more about our digital, operational, strategy and technology solutions. Many of our discussions were focused on how technology and improved operations help companies bring new therapies to market at speed. Our Accenture Life Sciences Cloud technology platform was a prominent attraction, with clients and prospects wanting to learn more about how Accenture Life Sciences Cloud is driving industry change through its collaborative design and providing companies with actionable insights from their clinical, regulatory, operational and safety data. Our clinical data team was represented in an all-day session with other R&D subject matter experts, to discuss collaborative development of an open source data repository for standard analysis using cloud service.
The discussion didn’t end there. We also hosted an Accenture Life Sciences Cloud Coalition meeting, which assembled leading R&D executives from top global pharmaceutical and biotechnology companies who are harnessing the platform to rethink, reshape and restructure R&D to accelerate the drug development and approval process for their companies.
To learn more, read about: